Sat, Dec 20, 2014, 11:02 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Orexigen Therapeutics, Inc. (OREX) Message Board

  • aosjdhdjduryffjfjfj aosjdhdjduryffjfjfj Jul 15, 2010 5:02 PM Flag

    Vivus rejection means the end of OREX

    The fda will never aprove obesity drug after phen-phen disaster many years ago. Orex has no value, only hype
    and clever marketing tricks to dupe investors, i mean ,gamblers. Try a casino... You will lose to, but more fun.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • OREX's Contrave doesn't use Fen-Phen. The rejection of Qnexa shows the FDA wants safety, and Contrave looks like a candidate to gain approval.

    • I guess you lost big in vvus! FDA was looking at safety alone. They even said efficacy is a non-issue! Sorry phen has a bad history and is no good when it comes to safety. One or two of these products will make it to the market! And yes many are betting! My bet is here do to the less safety issue that contrave has. If you look at any drugs pi you would probably not take the medication. That being said the products to make contrave has been on the market and has history, good history vs. Phen's bad history

      • 1 Reply to mobetter39
      • Isn`t safety the most important thing ??
        Efficacy studies are done all the time, especially
        in the big pharma arena. It must be known, though, that safety takes precedence over efficacy when an FDA decision is rendered. By the way, Vivus just opened-down 70%-


        As an aside,
        Contrave has 2 chances of winning approval in January:

        1) SLIM - less than 2% probability
        2) none- that means zero

        So, hopefully OREX has more drugs in the pipeline. Perhaps
        a pill for severe Depression, since most shareholders(me included) will
        need one after the contrave announcement.

 
OREX
6.33+0.04(+0.64%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.